PD Dr. med. Christian Meisel studied in parallel Medicine and Informatics and trained in General Internal Medicine, Oncology, Intensive Care, Cardiology, and Clinical Pharmacology. He is board-certified in both Internal Medicine and in Clinical Pharmacology. During his academic career, his main scientific interests were precision medicine, pharmacogenomics, and the genetic dissection of complex diseases. He published more than 40 peer reviewed publications, and has contributed to numerous books and served as Associate Professor, and Head of the Drug Therapy Information and Consultation Service of Charité University Medicine in Berlin, as well as the Scientific Managing Director and Head of the Information Center of the Research Alliance "Pharmacogenetics and pharmacogenetic diagnostics: improving therapy and drug development". In addition, he was the German delegate for the European Association for Clinical Pharmacology and Therapeutics (EACPT), member of the Drug Commission of the German Medical Association as well as member of the Ethics Committee of the Chamber of Physicians of Berlin. He joined Roche Headquarters in Basel in Global Pharma Development in 2004, where he was responsible for the medical genetics strategies of the development compounds. In 2006, Dr. Meisel moved to Roche Penzberg, where he took over global responsibility for Oncology Biomarkers across early and late-stage development. In 2010, he became Site Leader Oncology & Head Translational Medicine, and subsequently European Head of Translational Medicine, was acting Global Head Translational Medicine, before taking on the roles of Global Head Personalized Healthcare Platforms and Site Head, Roche Innovation Center Munich at Roche.